株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

セリアック病:機会評価、疫学予測、市場力学、パイプライン分析

Celiac Disease: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics, H2 2019

発行 GervanoRA Data Services LLP 商品コード 920042
出版日 ページ情報 英文 137 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.19円で換算しております。
Back to Top
セリアック病:機会評価、疫学予測、市場力学、パイプライン分析 Celiac Disease: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics, H2 2019
出版日: 2020年01月03日 ページ情報: 英文 137 Pages
概要

当レポートでは、世界のセリアック病治療薬市場について調査分析し、現在・将来の機会に焦点を当てて、市場価値、特許分析、市場シェアなどについて、体系的な情報を提供しています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 疾患の概要

  • 疾患の定義と症状
  • 病因と分類
  • 疾患の診断
  • 治療アルゴリズムとガイドライン
  • 疫学研究
  • 疫学予測

第4章 市場力学

  • 取引 (M&A、提携)
  • 特許分析 (失効、ジェネリック医薬品)

第5章 パイプライン分析

  • パイプライン分析:開発段階別
  • パイプライン分析:地域別
  • パイプライン分析:作用機序別
  • パイプライン分析:標的別
  • パイプライン分析:企業のタイプ別
  • パイプライン分析:大学・機関別

第6章 パイプライン薬の承認スケジュールの予測

第7章 臨床段階のパイプライン薬の説明と開発のマイルストーン

第8章 競合ベンチマーキングによる機会の評価

第9章 現在・将来の競合情勢

  • 既存企業
  • 新興企業

第10章 略語

目次
Product Code: GERPH648

GervanoRA's pipeline analysis and opportunity assessment report "Celiac Disease: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics, H2 2019" analyzed and assessed Celiac Disease pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Celiac Disease industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Celiac Disease area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Celiac Disease industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Drug Class, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Stage of development, Pipeline Analytics by Target and Pipeline Analytics by Companies.

Our comprehensive analysis on the Celiac Disease drug pipeline identified a total of 25 drug candidates undergoing different stages of development- from Early R&D to Phase 3 stage. Among these, one molecule is in the Phase 3 stage of development, five molecules are in Phase 2, one molecule is in Phase 1 and a total of 18 molecules are in non clinical stage of development. We have also identified four drug molecules that are inactive with no drug updates from the year 2015 or have been discontinued.

The report has covered more than 25 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 14 Emerging companies in the domain and hence deriving the key leader.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Epidemiology and Epidemiology forecast till 2025
  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
  • Patent Analytics of Pipeline Molecules
  • Pipeline Analysis and Estimated Pipeline Drug Approval Time lines of all Clinical Stage Pipeline Drug Candidates
  • Current and Future Competitive Landscape
  • Key Established Company Profiles with SWOT Analysis
  • Emerging Company Profiles with Opportunity Assessments

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2 KEY EVENTS IN THE CELIAC DISEASE COMPETITIVE SPACE
  • 2.3. REPORT MAJOR FINDINGS
    • 2.3.1. DRIVERS
    • 2.3.2. RESTRAINTS
    • 2.3.3. OPPORTUNITIES

3. CELIAC DISEASE OVERVIEW

  • 3.1. DISEASE DEFINITION AND SYMPTOMS
  • 3.2. DISEASE CAUSE AND CLASSIFICATION
  • 3.3. DISEASE DIAGNOSIS
  • 3.4. TREATMENT ALGORYTHM AND GUIDELINES
  • 3.5. EPIDEMIOLOGY STUDIES
  • 3.6. EPIDEMIOLOGY FORECAST
    • 3.6.1. FORECAST METHODOLOGY AND ASSUMPTIONS
    • 3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

4. MARKET DYNAMICS OF CELIAC DISEASE COMPETITIVE SPACE

  • 4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)
    • 4.1.1 DEALS ANALYTICS BY DEAL TYPE
    • 4.1.2 DEALS ANALYTICS BY ANNUAL FREQUENCY
    • 4.1.3 DEALS ANALYTICS BY ACTIVE PLAYERS
  • 4.2. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
    • 4.2.1. PATENT ANALYTICS OF PIPELINE DRUGS

5. PIPELINE DRUGS ANALYTICS OF CELIAC DISEASE

  • 5.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT
    • 5.1.1. PHASE 3 PIPELINE DRUGS
    • 5.1.2. PHASE 2 PIPELINE DRUGS
    • 5.1.3. PHASE 1 PIPELINE DRUGS
    • 5.1.4. PRECLINICAL PIPELINE DRUGS
    • 5.1.5. EARLY R&D PIPELINE DRUGS
    • 5.1.6. INACTIVE AND DISCONTINUED PIPELINE DRUGS
  • 5.2. PIPELINE DRUGS ANALYTICS BY GEOGRAPHY
    • 5.2.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.3. PIPELINE DRUGS ANALYTICS BY MECHANISM OF ACTION
    • 5.3.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.4. PIPELINE DRUGS ANALYTICS BY TARGET
  • 5.5. PIPELINE DRUGS ANALYTICS BY COMPANY TYPE
  • 5.6. PIPELINE DRUGS ANALYTICS BY UNIVERSITIES AND INSTITUTES - LICENSING OPPORTUNITIES

6. CLINICAL STAGE PIPELINE DRUG DESCRIPTIONS AND DEVELOPMENT MILESTONES

  • 6.1. PHASE 3 PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • LARAZOTIDE ACETATE OR INN-202
  • 6.2. PHASE 2 PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • AMG 714/PRV-015
  • LATIGLUTENASE (IMGX003)
  • TAK-101/CNP-101
  • ZED1227
  • BL-7010
  • MIK-BETA-1
  • 6.3. PHASE 1 PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • KUMA062
  • AG017
  • NECATORAMERICANUS (HOOKWORM) LARVAE
  • ANTI-GLUTEN IMMUNOGLOBULIN YOLK ANTIBODIES

7. ESTIMATED APPROVAL TIMELINES OF CELIAC DISEASE PIPELINE DRUGS

  • 7.1. METHODOLOGY
  • 7.2. ESTIMATED APPROVAL TIMELINES US & EX-US

8. OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

  • 8.1. EXTERNAL DEPENDENCIES
  • 8.2. PIPELINE PORTFOLIO
  • 8.3. EXPECTED MARKET ENTRIES
  • 8.4. PATENTS AND EXCLUSIVITY
  • 8.5. MARKET DYNAMICS WITH PARTNERING ACTIVITIES
  • 8.6. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES
  • 8.7. COMPANY DEVELOPMENTS

9. ASSESSMENT OF CURRENT AND FUTURE COMPETITIVE LANDSCAPE THROUGH COMPANY PROFILES

  • 9.1. ESTABLISHED COMPANIES
    • 9.1.1. KEY COMPANY PROFILES AND SWOT ANALYSIS
      • 9.1.1.1. AMGEN INC
      • 9.1.1.2. GLAXOSMITHKLINE PLC
      • 9.1.1.3. TAKEDA PHARMACEUTICAL CO., LTD.
  • 9.2. EMERGING COMPANIES
    • 9.2.1. KEY EMERGING COMPANY PROFILES
      • 9.2.1.1 INNOVATE BIOPHARMACUETICALS INC
      • 9.2.1.2. IMMUNOGENX LLC
      • 9.2.1.3. IMMUSANT INC
      • 9.2.1.4. PVP BIOLOGICS INC
      • 9.2.1.5. COUR PHARMACEUTICALS
      • 9.2.1.6. ZEDIRA GMBH
      • 9.2.1.7. ACTOBIO THERAPEUTICS, INC
      • 9.2.1.8. BIOLINERX
      • 9.2.1.9. AMYRA BIOTECH AG
      • 9.2.1.10. ANOKION SA
      • 9.2.1.11. ANTOLRX INC
      • 9.2.1.12. BIONIZ THERAPEUTICS INC
      • 9.2.1.13. IM THERAPEUTICS
      • 9.2.1.14. AHEAD THERAPEUTICS

10. ABBREVIATIONS

LIST OF TABLES

  • TABLE 1: REPORT HIGHLIGHTS IN NUMERICAL
  • TABLE 2: GLOBAL CELIAC DISEASE POPULATION, MILLION (2018-2019)
  • TABLE 3: TOP 5 DEALS INVOLVING CELIAC DISEASE, RANKED BY DEAL AMOUNT
  • TABLE 4: CELIAC DISEASE COLLABORATION DEALS
  • TABLE 5: CELIAC DISEASE LICENSING DEALS
  • TABLE 6: CELIAC DISEASE MERGER AND ACQUISITION DEALS
  • TABLE 7: CELIAC DISEASE FINANCING DEALS
  • TABLE 8: PHASE 2 CELIAC DISEASE MOLECULES
  • TABLE 9: PRECLINICAL CELIAC DISEASE MOLECULES
  • TABLE 10: EARLY R&D CELIAC DISEASE MOLECULES
  • TABLE 11: INACTIVE AND DISCONTINUED CELIAC DISEASE MOLECULES
  • TABLE 12: CELIAC DISEASE PIPELINE ANALYTICS BY TARGET
  • TABLE 13: CELIAC DISEASE PIPELINE ANALYTICS BY COMPANY TYPE
  • TABLE 14: CELIAC PIPELINE DRUGS BY UNIVERSITIES AND INSTITUTES
  • TABLE 15: ESTIMATED APPROVAL TIMELINES OF KEY CELIAC DISEASE PIPELINE DRUGS
  • TABLE 16: RANKING OF TOP EMERGING COMPANIES BASED ON REGULATORY ALLOWANCES
  • TABLE 17: MAJOR PRODUCTS OF AMGEN WITH SALES IN FIRST NINE MONTHS FOR 2018 AND 2019 RESPECTIVELY
  • TABLE 18: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO HEMATOLOGY/ONCOLOGY THERAPEUTIC AREA
  • TABLE 19: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO INFLAMMATORY THERAPEUTIC AREA
  • TABLE 20: RESEARCH AND DEVELOPMENT ACTIVITIES OF AMGEN
  • TABLE 21: RECENT DEVELOPMENTS OF AMGEN
  • TABLE 22: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO ONCOLOGY THERAPEUTIC AREA
  • TABLE 23: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO HIV AND INFECTIOUS DISEASE THERAPEUTIC AREA
  • TABLE 24: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO IMMUNO-INFLAMMATION THERAPEUTIC AREA
  • TABLE 25: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO IMMUNO-INFLAMMATION THERAPEUTIC AREA
  • TABLE 26: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO VACCINES
  • TABLE 27: RESEARCH AND DEVELOPMENT ACTIVITIES OF GSK
  • TABLE 28: RECENT DEVELOPMENTS OF GSK
  • TABLE 29: MAJOR PRODUCTS OF TAKEDA
  • TABLE 30: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO ONCOLOGY THERAPEUTIC AREA
  • TABLE 31: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO GASTROENTEROLOGY THERAPEUTIC AREA
  • TABLE 32: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO RARE DISEASE THERAPEUTIC AREA
  • TABLE 33: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO NEUROSCIENCE THERAPEUTIC AREA
  • TABLE 34: RESEARCH AND DEVELOPMENT ACTIVITIES OF TAKEDA
  • TABLE 35: RECENT DEVELOPMENTS OF TAKEDA
  • TABLE 36: COUR PRODUCT PIPELINE
  • TABLE 37: COUR RECENT DEVELOPMENTS
  • TABLE 38: ZEDIRA PRODUCT PIPELINE
  • TABLE 39: ZEDIRA RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 40: ZEDIRA RECENT DEVELOPMENTS
  • TABLE 41: ZEDIRA CONFERENCES
  • TABLE 42: ZEDIRA ARTICLES
  • TABLE 43: ZEDIRA 2020 EVENTS
  • TABLE 44: ACTOBIO PRODUCT PIPELINE
  • TABLE 45: ACTOBIO RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 46: ACTOBIO RECENT DEVELOPMENTS
  • TABLE 47: ACTOBIO PRESENTATIONS
  • TABLE 48: BIOLINERX PRODUCT PIPELINE
  • TABLE 49: RESEARCH AND DEVELOPMENT ACTIVITIES OF BIOLINERX
  • TABLE 50: BIOLINERX RECENT DEVELOPMENTS
  • TABLE 51: BIOLINERX PRESENTATIONS
  • TABLE 52: BIOLINERX COLLABORATIONS
  • TABLE 53: ANTOLRX PRODUCT PIPELINE
  • TABLE 54: ANTOLRX RECENT DEVELOPMENTS
  • TABLE 55: ANTOLRX CONFERENCES
  • TABLE 56: ANTOLRX PUBLICATIONS
  • TABLE 57: BIONIZ PRODUCT PIPELINE
  • TABLE 58: BIONIZ RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 59: BIONIZ RECENT DEVELOPMENTS
  • TABLE 60: IM THERAPEUTICS PRODUCT PIPELINE
  • TABLE 61: IM THERAPEUTICS RECENT DEVELOPMENTS
  • TABLE 62: IM THERAPEUTICS PUBLICATIONS
  • TABLE 63: PVP BIOLOGICS RECENT DEVELOPMENTS
  • TABLE 64: IMMUSANT PRODUCT PIPELINE
  • TABLE 65: IMMUSANT RESEARCH AND DEVELOPMENTS
  • TABLE 66: IMMUSANT RECENT DEVELOPMENTS
  • TABLE 67: IMMUSANT EVENTS AND CONFERENCES
  • TABLE 68: IMMUSANT PRESENTATIONS
  • TABLE 69: IMMUSANT PUBLICATIONS
  • TABLE 70: INNOVATE PRODUCT PIPELINE
  • TABLE 71: INNOVATE RESEARCH AND DEVELOPMENTS
  • TABLE 72: INNOVATE RECENT DEVELOPMENTS
  • TABLE 73: INNOVATE COLLABORATIONS
  • TABLE 74: INNOVATE PRESENTATIONS
  • TABLE 75: AHEAD THERAPEUTICS PRODUCT PIPELINE
  • TABLE 76: AHEAD THERAPEUTICS RESEARCH AND DEVELOPMENTS
  • TABLE 77: AHEAD THERAPEUTICS RECENT DEVELOPMENTS
  • TABLE 78: AMYRA PRODUCT PIPELINE
  • TABLE 79: ANOKION PRODUCT PIPELINE
  • TABLE 80: ANOKION RESEARCH AND DEVELOPMENTS
  • TABLE 81: ANOKION RECENT DEVELOPMENTS
  • TABLE 82: ANOKION PUBLICATIONS
  • TABLE 83: IMMUNOGENX PRODUCT PIPELINE
  • TABLE 84: IMMUNOGENX RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 85: IMMUNOGENX RECENT DEVELOPMENTS
  • TABLE 86: IMMUNOGENX EVENTS AND CONFERENCES

LIST OF FIGURES

  • FIGURE 1: KEY EVENTS IN CELIAC DISEASE AREA
  • FIGURE 2: GLOBAL EPIDEMILOGY FORECAST OF CELIAC DISEASE, IN MILLION (2018-2025)
  • FIGURE 3: CELIAC DISEASE DEAL ANALYTICS BY DEAL TYPE
  • FIGURE 4: CELIAC DISEASE DEAL ANALYTICS BY DEAL FREQUENCY
  • FIGURE 5: DEALS ANALYTICS BY ACTIVE PLAYERS WITH RESPECT TO CELIAC DISEASE TREATMENTS
  • FIGURE 6: CELIAC DISEASE MOLECULES WITH RESPECT TO STAGE OF DEVELOPMENT
  • FIGURE 7: CELIAC DISEASE PIPELINE SPLIT UP BY GEOGRAPHY
  • FIGURE 8: CELIAC DISEASE PIPELINE SPLIT UP WITH RESPECT TO ROA
  • FIGURE 9: CELIAC DISEASE PIPELINE ANALYTICS BY COMPANY TYPE
  • FIGURE 10: PIPELINE PORTFOLIO WITH (NUMBER OF MOLECULES)
  • FIGURE 11: EXPECTED MARKET ENTRY IN THE U.S IN CELIAC DISEASE TREATMENT
  • FIGURE 12: PATENT PORTFOLIO COMPARISON OF TOP 10 EMERGING COMPANIES
  • FIGURE 13: TIME LINE OF PATENT EXPIRIES IRRESPECTIVE OF CELIAC DISEASE TREATMENTS
  • FIGURE 14: TIME LINE OF PATENT EXPIRIES WITH RESPECT TO CELIAC DISEASE
  • FIGURE 15: RANKING TOP 6 EMERGING COMPANIES BASED ON THEIR PARTNERING ACTIVITIES
  • FIGURE 16: R&D EXPENSES AS WELL AS NET SALES FOR YEARS 2016, 2017 AND 2018 MADE BY AMGEN
  • FIGURE 17: PRODUCT SALES AND R&D EXPENSES FOR THE FIRST NINE MONTHS OF 2018 AND 2019
  • FIGURE 18: GSK'S RESEARCH AND DEVELOPMENT EXPENSES AND NET SALES FOR 2017 AND 2018
  • FIGURE 19: GSK'S SALES BREAKDOWN FOR FIRST NINE MONTHS OF 2019
  • FIGURE 20: GSK'S GLOBAL AND PHARMACEUTICAL BUSINESS SEGMENT SALE BREAKDOWN FOR NINE MONTHS IN 2019
  • FIGURE 21: GSK'S GLOBAL AND VACCINES BUSINESS SEGMENT SALE BREAKDOWN FOR NINE MONTHS IN 2019
  • FIGURE 22: GSK'S GLOBAL & CUSTOMER HEALTHCARE BUSINESS SEGMENT SALE BREAKDOWN FOR 09 MONTHS IN 2019
  • FIGURE 23: REVENUES ATTAINED AND R&D EXPENSES BY TAKEDA ENDED ON 31 MARCH 2018 AND 2019
  • FIGURE 24: GEOGRAPHICAL DISTRIBUTION OF REVENUES EARNED BY TAKEDA IN 2019
  • FIGURE 25: NET LOSSES FOR THE YEAR ENDED DECEMBER 31, 2018, 2017, 2016 (THOUSAND DOLLARS)
  • FIGURE 26: RESEARCH AND DEVELOPMENT EXPENSES FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2017
Back to Top